Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer

Bristol-Myers Squibb (BMS)

Status and phase: Terminated; Phase 2

Conditions: Non-small Cell Lung Cancer

Treatments: Drug: BMS-275183

Study type: Interventional

Funder types: Industry

Identifiers

NCT00099879

CA165-020

Details and patient eligibility

About

The purpose of this clinical research study is to learn if BMS-275183 can shrink or slow the growth of the cancer in subjects with non-small cell lung cancer (NSCLC). The safety of this treatment will also be studied.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced or metastatic pretreated NSCLC
• Measurable disease
• Adequate hematologic, hepatic and renal functions
• ECOG Performance Status of 0-2

Exclusion criteria

• Inability to swallow capsules
• Recent significant cardiovascular disease
• Woman who are pregnant or breastfeeding